• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

    0.2498 +0.0079 (+3.27%)
    Streaming Delayed Price Updated: 11:20 AM EDT, Oct 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mainz Biomed N.V. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Mainz Biomed Provides Full Year 2022 Financial Results
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
    From Mainz BioMed NV
    Via GlobeNewswire
    Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates ($MYNZ)
    Via AB Newswire
    Mainz Biomed ($MYNZ) Inks Accretive Partnership To Expand Marketing Reach Of ColoAlert Diagnostic, Analysts Model For Over 72% Upside ($MYNZ)
    Via AB Newswire
    Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
    Labor Staber to actively market and sell ColoAlert to its physician and patient network. 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
    From Mainz BioMed NV
    Via GlobeNewswire
    In Focus: Mainz Biomed Nears Multiple Data Set Releases Expected To Fuel 2023 Growth ($MYNZ)
    Via AB Newswire
    Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed In Focus Ahead Of Two Data-Set Releases In 1H/2023 ($MYNZ)
    Via AB Newswire
    Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
    Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
    Virtual Fireside Chat via Paltalk Platform 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed’s Milestones Reached In 2022 Can Be Catalysts In 1/H 2023…Here’s Why ($MYNZ)
    Via AB Newswire
    Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
    Continued roll-out in Europe with onboarding of new lab partners 
    From Mainz BioMed NV
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
    Via Benzinga
    Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
    Patient Access Initiative Addresses €1 Billion Annual Market in Germany 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Provides Year-End 2022 Corporate Review
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket
    Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday. 
    Via Benzinga
    Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
    Via InvestorPlace
    Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
    Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Provides Third Quarter 2022 Update
    From Mainz BioMed NV
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
    Upgrades 
    Via Benzinga
    Mainz Biomed’s Colorectal And Pancreatic Cancer Screening Diagnostics Are More Than Life Savers, They Are Significant Value Drivers ($MYNZ)
    Via AB Newswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.